Graziano Seghezzi, Managing Partner, joined Sofinnova Partners in 2006 and is an active member of the investment team in the Sofinnova Capital Funds.
Graziano serves on the Board of Directors of several companies for which he has participated in the creation and seed financing, including Mission Therapeutics, Crescendo Biologics, Hotspot Therapeutics, Polyneuron and Erydel. He also established Italy’s first biotech accelerator, BiovelocITA, and the Sofinnova Telethon Fund.
Graziano was responsible for numerous substantial exits, including Corvidia Therapeutics, which was sold to Novo Nordisk for €2.1 billion in 2020. In addition, Hookipa Pharma floated on the Nasdaq in 2019, GlycoVaxyn was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals went public on the Nasdaq in 2013 and was subsequently sold to AstraZeneca in the same year.
Graziano started his career in venture capital in 2001 at Sofinnova Partners and was at Index Ventures from 2003 to 2006. Prior to that, Graziano spent five years working in academic research at New York University’s School of Medicine, studying oncology and cardiovascular diseases. Graziano holds a degree in genetics and microbiology from the University of Pavia, Italy, and an MBA from RSM-Erasmus University, The Netherlands.